Study on the Efficacy and Mechanism of METTL3 Peptide Inhibitors in Enhancing Anti-tumor Immune Response by Reshaping the Tumor Microenvironment

Not yet recruiting

• Conditions: Bladder Cancer; Prostate Cancer; Kidney Cancer

• Registration Number: NCT06762925
• Lead Sponsor: Xijing Hospital

Brief Summary

This study aims to validate the accuracy and clinical value of METTL3 as a biomarker for predicting immune therapy response in patients with urinary tract tumors through observational studies.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-11-21
• Status Verified: 2024-12
• Study First Submitted QC: 2025-01-07
• Last Update Submitted: 2025-01-07
• Study First Posted: 2025-01-08
• Last Update Posted: 2025-01-08
• Study Start: 2025-01-30
• Primary Completion: 2026-06-01
• Study Completion: 2026-06-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 450

Inclusion Criteria

1. Patients diagnosed with urinary system tumors through pathological examination;
2. Meet specific clinical stages and surgical treatment standards;
3. Intraoperative tissue resection meets the sample testing standards;
4. The patient is willing to participate in the study and sign an informed consent form.

Exclusion Criteria

1. Not meeting the specific clinical stage and not receiving surgical treatment;
2. Abnormal mental behavior;
3. Intellectual disability;
4. Age under 18 years old or over 75 years old;
5. Low understanding and communication skills.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The expression levels of METTL3 and ANGPTL2	About a year and a half